肾癌预后评估:近期进展与未来方向
本文综述肾细胞癌(RCC)在局限期与转移期中的预后因素与分期系统。局限期传统依据解剖范围进行风险分层,已有多个整合评分系统预测根治性局部治疗后的结局;转移期已建立整合预后模型,用于临床试验分层和临床风险导向治疗选择。分子与基因组改变的预后作用仍在积极研究中,未来方向包括分子生物标志物整合入传统模型。
要点
- 局限期RCC风险分层传统依据解剖范围,已有整合评分系统预测局部治疗后结局。
- 转移期RCC已建立整合预后模型,用于试验分层与临床风险导向治疗选择。
- 分子与基因组改变的预后价值仍在研究中,未来将整合入传统预后模型。
核心结论
- 局限期与转移期RCC均有多种临床、病理和分子预后因素,整合模型已用于风险分层和治疗选择。
研究设计与样本
- 本文为综述,总结局限期与转移期RCC的当前分期系统与预后因素,并探讨分子生物标志物整合的未来方向。
主要发现
- 局限期RCC传统风险分层涉及解剖范围,多个整合评分系统已开发用于预测根治性局部治疗后的结局。
- 转移期RCC已建立整合预后模型,用于当代临床试验分层和临床实践中的风险导向治疗选择。
- 局限期与转移期RCC的预后因素有许多共同点,但也存在重要区别。
- 特定分子与基因组改变的预后作用在局限期和转移期均是活跃研究领域。
临床怎么用
- 转移期RCC可使用整合预后模型进行风险分层,辅助临床试验分层和临床风险导向治疗选择。
- 局限期RCC可使用整合评分系统预测根治性局部治疗后的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The most common type of cancer originating in the kidney is renal cell carcinoma (RCC). In both localized and advanced RCC, a number of clinical, pathologic, and molecular factors have been identified as having prognostic significance. In localized disease, risk stratification has traditionally involved the anatomic extent of disease, and several integrated scoring systems have been developed to help predict outcomes after definitive local therapy. In metastatic RCC, integrated prognostic models have also been established. These are used to stratify patients in contemporary clinical trials and to guide risk-directed treatment selection in clinical practice. Although many prognostic factors are common to both localized and advanced disease, there are some important distinctions. In both of these types of disease, the prognostic role of specific molecular and genomic alterations is an area of active investigation. In this review, we highlight the current staging systems and prognostic factors in localized and metastatic RCC. We also explore future directions in this area, including the expanding role of molecular biomarkers and their integration into the traditional prognostic models.
引用
- Graham J, Dudani S, Heng DYC, et al. Prognostication in Kidney Cancer: Recent Advances and Future Directions. J Clin Oncol. 2018. PMID: 30372388. doi:10.1200/JCO.2018.79.0147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。